D. Kishino

发表

Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.

K. Eguchi, K. Hotta, M. Nakata, 2000, Anticancer research.

Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.

K. Kiura, M. Tabata, H. Ueoka, 2010, Lung cancer.

Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors

K. Kiura, K. Hotta, Y. Maeda, 2021, Journal of Cancer Research and Clinical Oncology.

Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.

K. Kiura, K. Hotta, Y. Maeda, 2020, Japanese journal of clinical oncology.

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

K. Kiura, K. Hotta, Y. Maeda, 2020, Cancer science.

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

K. Kiura, K. Hotta, Y. Maeda, 2020, Cancer Immunology, Immunotherapy.

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

K. Kiura, M. Tabata, H. Ueoka, 2011, Lung cancer.

A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2009, Lung cancer.

Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2005, Internal medicine.

Two cases of atypical carcinoid of the thymus.

K. Eguchi, M. Ida, M. Nakata, 2000, Internal medicine.

A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study

K. Kiura, M. Tabata, H. Ueoka, 2007, Cancer Chemotherapy and Pharmacology.

Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.

K. Kiura, M. Tanimoto, K. Ohashi, 2009, Lung cancer.

Phase II Study of the EGFR‐TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403

K. Kiura, M. Tanimoto, K. Hotta, 2017, Clinical lung cancer.

Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.

K. Matsuo, H. Ueoka, K. Tajima, 2007, Asian Pacific journal of cancer prevention : APJCP.

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

K. Kiura, M. Tabata, H. Ueoka, 2015, Lung cancer.

Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?

K. Kiura, M. Tabata, H. Ueoka, 2005, Anticancer research.

Clinical investigation of bronchioloalveolar carcinoma: a retrospective analysis of 53 patients in a single institution.

M. Shimono, K. Hotta, M. Nakata, 1999, Anticancer research.

The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.

K. Kiura, K. Hotta, Y. Maeda, 2019, Lung cancer.

Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.

K. Kiura, K. Hotta, Y. Maeda, 2021, European journal of cancer.

Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?

K. Kiura, H. Ueoka, M. Tanimoto, 2011, Acta medica Okayama.

A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.

K. Kiura, M. Tanimoto, K. Hotta, 2017, Lung cancer.

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.

K. Kiura, K. Hotta, Y. Maeda, 2021, European journal of cancer.

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

K. Kiura, M. Tabata, H. Ueoka, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

K. Kiura, M. Tabata, H. Ueoka, 2014, European journal of cancer.

Three‐Arm Randomized Trial of Sodium Alginate for Preventing Radiation‐Induced Esophagitis in Locally Advanced Non–Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol

K. Kiura, M. Tanimoto, K. Katsui, 2017, Clinical lung cancer.

Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice.

K. Kiura, H. Ueoka, M. Tanimoto, 2012, Acta medica Okayama.

Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity.

K. Eguchi, S. Takashima, M. Ida, 2000, International journal of radiation oncology, biology, physics.

Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

K. Kiura, M. Tabata, H. Ueoka, 2004, Cancer Chemotherapy and Pharmacology.

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study

K. Kiura, K. Hotta, T. Tamura, 2022, Cancers.

Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.

K. Kiura, M. Tabata, K. Hotta, 2023, Respiratory investigation.

Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice.

K. Kiura, H. Ueoka, M. Tanimoto, 2023, Acta Medica Okayama.

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol

Kayo Nakamura, N. Miyahara, Y. Maeda, 2023, Respiratory medicine case reports.

More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance

K. Kiura, K. Hotta, T. Tamura, 2022, Journal of Cancer Research and Clinical Oncology.

Clinical investigation of atypical adenomatous hyperplasia of the lung.

K. Eguchi, M. Ida, M. Shimono, 1999, Lung cancer.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

K. Kiura, M. Tabata, H. Ueoka, 2014, European journal of cancer.

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

K. Kiura, M. Tabata, H. Ueoka, 2011, Lung cancer.